Resultados de Búsqueda
Follow the recommendations in the NICE service guidelines on improving outcomes in urological cancers and improving supportive and palliative care for adults with cancer.
NICE
National Institute for Health and Clinical Excellence (NICE)
Offer people with prostate cancer information tailored to their own needs. This information should be given by a healthcare professional (for example, a consultant or specialist nurse) and may be supported by written and visual media. Offer people with prostate cancer advice on how to get information and support from websites, local and national cancer information services, and from cancer support groups. Choose or recommend information resources for people with prostate cancer that are ...
ver más ... 2019Enzalutamide is not recommended, within its marketing authorisation, for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with enzalutamide that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Currently, when prostate cancer no longer responds to hormone treatment (androgen deprivation therapy), but has not yet spread ...
ver más ... 2019Nusinersen is recommended to treat 5MA spinal muscular atrophy (SMA) only if people have pre-symptomatic SMA, or SMA types 1, 2, or 3 and the conditions of the managed access agreement are followed.
NICE
National Institute for Health and Clinical Excellence (NICE)
SMA is a rare genetic condition, the most severe types of which affect babies and young children. Currently, there is an unmet need for effective treatments that could slow disease progression. Clinical trial evidence shows that nusinersen improves a range of outcomes that are important to people with early- (type 1) and later-onset (types 2 and 3) SMA. Also, there is some evidence suggesting that nusinersen is effective for pre-symptomatic SMA. However, there is no long-term evidence, so the ...
ver más ... 2019Oral bisphosphonates (alendronic acid, ibandronic acid, and risedronate sodium) and intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Are recomended in adults: - who are eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and NICE's quality standard on osteoporosis and - who have been assessed as being at higher risk of osteoporotic fragility fracture using the methods recommended in NICE's guideline on osteoporosis (recommendations 1.3 to 1.12) and NICE's quality standard on osteoporosis and - when bisphosphonate treatment is appropriate, taking into account their risk ...
ver más ... 2019Refer in line with local pathways if symptoms of carpal tunnel syndrome are severe or persistent after initial management.
NICE
The committee noted that carpal tunnel syndrome is common and many regions have established management pathways that might not involve neurological services.
ver más ... 2019